These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29278418)

  • 41. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.
    Gumy-Pause F; Pardo B; Khoshbeen-Boudal M; Ansari M; Gayet-Ageron A; Sappino AP; Attiyeh EF; Ozsahin H
    Genes Chromosomes Cancer; 2012 Feb; 51(2):174-85. PubMed ID: 22045684
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis.
    Donizy P; Kaczorowski M; Leskiewicz M; Zietek M; Pieniazek M; Kozyra C; Halon A; Matkowski R
    Oncol Rep; 2014 Dec; 32(6):2735-43. PubMed ID: 25310673
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis.
    Marzese DM; Scolyer RA; Huynh JL; Huang SK; Hirose H; Chong KK; Kiyohara E; Wang J; Kawas NP; Donovan NC; Hata K; Wilmott JS; Murali R; Buckland ME; Shivalingam B; Thompson JF; Morton DL; Kelly DF; Hoon DS
    Hum Mol Genet; 2014 Jan; 23(1):226-38. PubMed ID: 24014427
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nucleoli cytomorphology in cutaneous melanoma cells - a new prognostic approach to an old concept.
    Donizy P; Biecek P; Halon A; Maciejczyk A; Matkowski R
    Diagn Pathol; 2017 Dec; 12(1):88. PubMed ID: 29284501
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Silencing of the thrombomodulin gene in human malignant melanoma.
    Furuta J; Kaneda A; Umebayashi Y; Otsuka F; Sugimura T; Ushijima T
    Melanoma Res; 2005 Feb; 15(1):15-20. PubMed ID: 15714116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
    Castelo-Branco P; Choufani S; Mack S; Gallagher D; Zhang C; Lipman T; Zhukova N; Walker EJ; Martin D; Merino D; Wasserman JD; Elizabeth C; Alon N; Zhang L; Hovestadt V; Kool M; Jones DT; Zadeh G; Croul S; Hawkins C; Hitzler J; Wang JC; Baruchel S; Dirks PB; Malkin D; Pfister S; Taylor MD; Weksberg R; Tabori U
    Lancet Oncol; 2013 May; 14(6):534-42. PubMed ID: 23598174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
    Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
    Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
    Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
    J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer.
    Wang S; Dorsey TH; Terunuma A; Kittles RA; Ambs S; Kwabi-Addo B
    PLoS One; 2012; 7(5):e37928. PubMed ID: 22701537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour.
    Okamoto Y; Sawaki A; Ito S; Nishida T; Takahashi T; Toyota M; Suzuki H; Shinomura Y; Takeuchi I; Shinjo K; An B; Ito H; Yamao K; Fujii M; Murakami H; Osada H; Kataoka H; Joh T; Sekido Y; Kondo Y
    Gut; 2012 Mar; 61(3):392-401. PubMed ID: 21708825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genetic and epigenetic patterns in patients with the head-and-neck paragangliomas associate with differential clinical characteristics.
    Chen H; Zhu W; Li X; Xue L; Wang Z; Wu H
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):953-960. PubMed ID: 28255624
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer.
    Kim SH; Park KH; Shin SJ; Lee KY; Kim TI; Kim NK; Rha SY; Ahn JB
    Yonsei Med J; 2018 Jul; 59(5):588-594. PubMed ID: 29869456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin.
    Lahtz C; Stranzenbach R; Fiedler E; Helmbold P; Dammann RH
    J Invest Dermatol; 2010 Feb; 130(2):620-2. PubMed ID: 19798057
    [No Abstract]   [Full Text] [Related]  

  • 54. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.
    Gonzalgo ML; Bender CM; You EH; Glendening JM; Flores JF; Walker GJ; Hayward NK; Jones PA; Fountain JW
    Cancer Res; 1997 Dec; 57(23):5336-47. PubMed ID: 9393758
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.
    Gao L; van den Hurk K; Moerkerk PTM; Goeman JJ; Beck S; Gruis NA; van den Oord JJ; Winnepenninckx VJ; van Engeland M; van Doorn R
    J Invest Dermatol; 2014 Dec; 134(12):2957-2966. PubMed ID: 24999589
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma.
    Mitra S; Lauss M; Cabrita R; Choi J; Zhang T; Isaksson K; Olsson H; Ingvar C; Carneiro A; Staaf J; Ringnér M; Nielsen K; Brown KM; Jönsson G
    Mol Oncol; 2020 May; 14(5):933-950. PubMed ID: 32147909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
    Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
    Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
    Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome.
    Lawrence NF; Hammond MR; Frederick DT; Su Y; Dias-Santagata D; Deng A; Selim MA; Mahalingam M; Flaherty KT; Hoang MP
    J Am Acad Dermatol; 2016 Sep; 75(3):595-602. PubMed ID: 27543214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.